Oncology

GI Innovation Recruits Chief Executive Officer Byung-Geon Rhee Former CEO of GC Pharma, SCM Lifescience Corp.

Retrieved on: 
Friday, March 4, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Geon, IPO, KOSDAQ, Patient, Joon-ho, International Vaccine Institute, GI, Chemical engineering, Growth, Seoul National University, Multimedia, CEO, Clinical trial, IVI, Engineering, R, Regenerative medicine, Board of directors, CKD, CARM, Management, Pembrolizumab

GI Innovation , a new innovative drug development company, announced on March 4th that it has recruited Chief Executive Officer (CEO) and Chairman, Byung-Geon Rhee, former CEO of GC Pharma, SCM Lifescience Corp.

Key Points: 
  • GI Innovation , a new innovative drug development company, announced on March 4th that it has recruited Chief Executive Officer (CEO) and Chairman, Byung-Geon Rhee, former CEO of GC Pharma, SCM Lifescience Corp.
  • View the full release here: https://www.businesswire.com/news/home/20220304005106/en/
    Byung-Geon Rhee, CEO received a chemical engineering doctorate from William Marsh Rice University, the U.S. following the college of engineering Seoul National University and graduate school.
  • Byung-Geon Rhee, CEO of GI Innovation, said, GI Innovation has grown significantly for the past 4 years since the establishment.
  • Jun-Ho Hong, CEO of GI Innovation, said, Through the recruitment of Byung-Geon Rhee, CEO, we expect GI Innovations growth in many ways such as IPO, R&D, business strategies, etc.

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Retrieved on: 
Friday, March 4, 2022
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, EQUIP, Risk, Private Securities Litigation Reform Act, Harvard Medical School, Patient, Adult, HSCT, GVHD, Population, Asthma, Forward-looking statement, Vomiting, Disease, Itolizumab, IV, Safety, CR, FDA, Methylprednisolone, Degenerative disease, Alopecia areata, CD6, Nausea, ORR, SEC, Cancer, Rash, Trial of the century, EDGAR, Adolescence, Diarrhea, Jaundice, Mortality, Partnership, McMillan, Itch, Nasdaq, Incidence, Irritation, Skin discoloration, Feedback, Therapy, Pharmaceutical industry, Vaccine, Medicine, the EQUATOR Study, Equillium, THE EQUATOR STUDY, EQUILLIUM

The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.

Key Points: 
  • The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.
  • Our Phase 3 study is supported by the compelling results from our EQUATE study demonstrating rapid and durable complete responses in high-risk acute GVHD patients.
  • Hematologists and transplantation specialists have highlighted their enthusiasm for itolizumab as a potential therapeutic option and we are optimistic for these patients as we launch the EQUATOR study.
  • If successful in the EQUATOR study, itolizumab could result in the first approval of a novel therapeutic in the first-line treatment of acute GVHD, potentially transformative in the field.

Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit

Retrieved on: 
Friday, March 4, 2022
Health, Oncology, Risk, Laboratory developed test, Patient, Research, Forward-looking statement, Twitter, LDT, Security (finance), U.S. Securities and Exchange Commission, LSI, Instagram, FDA, Lucid, Club, Waldorf Astoria New York, Cancer, COVID-19, Time, CEO, Grand Terrace, California, Intention, GERD, Nasdaq, Therapy, Facebook

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate, in-person, at the LSI 22 Emerging Medtech Summit on March 15-18, 2022, at the Waldorf Astoria, Monarch Beach Resort & Club in Dana Point, California.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate, in-person, at the LSI 22 Emerging Medtech Summit on March 15-18, 2022, at the Waldorf Astoria, Monarch Beach Resort & Club in Dana Point, California.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.
  • Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 4, 2022
Biotechnology, Health, Oncology, Cancer, Bio, Employment, Patient, CAR, ACET, Nasdaq, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on February 28, 2022 (the Grant Date) under Adicets 2022 Inducement Plan as a material inducement to employment to three individuals hired by Adicet in February 2022.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on February 28, 2022 (the Grant Date) under Adicets 2022 Inducement Plan as a material inducement to employment to three individuals hired by Adicet in February 2022.
  • All of the above-described awards were granted outside of Adicets stockholder-approved equity incentive plans pursuant to Adicets 2022 Inducement Plan, which was adopted by the board of directors in January 2022.
  • The awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 4, 2022
Biotechnology, Pharmaceutical, Health, Oncology, European Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Employment, Patient, Tablet, Adult, Royal commission, Puma Biotechnology, View, Food, Capecitabine, FDA, Biotechnology, Financial compensation, NASDAQ, Pharmaceutical industry

The award was granted under Pumas 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.

Key Points: 
  • The award was granted under Pumas 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
  • The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • NERLYNX is a registered trademark of Puma Biotechnology, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220304005003/en/

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 4, 2022
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Terminology, Risk, Private Securities Litigation Reform Act, Employment, Patient, General counsel, Forward-looking statement, Central nervous system, Internet, Twitter, Public health, Security (finance), U.S. Securities and Exchange Commission, Blood, LinkedIn, SEC, COVID-19, Cancer, Senior, Target, Cerebrospinal fluid, Review, Technology, Physician, Facebook

The inducement stock option has a grant date of February 28, 2022, and was granted as an inducement material to Mr. Taylors entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The inducement stock option has a grant date of February 28, 2022, and was granted as an inducement material to Mr. Taylors entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement stock option is subject to the terms and conditions of Biocepts Amended and Restated 2013 Equity Incentive Plan.
  • Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Retrieved on: 
Thursday, March 3, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Risk, Microdeletion syndrome, Company, Lymphatic system, ID, Nasdaq, Corporation, Telephone, Webcast, Geron Corporation, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Companys website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Companys website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as upcoming milestones at 4:30 p.m.
  • A live webcast of the conference call and related presentation will be available on the Companys website at www.geron.com/investors/events .
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.

Artiva Biotherapeutics Appoints Laura Bessen, M.D., to Its Board of Directors

Retrieved on: 
Thursday, March 3, 2022
Research, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Internal medicine, Patient, Breast, DuPont (1802–2017), Bladder cancer, Lymphoid leukemia, Lymphoma, ADCC, Single-use medical devices, Biochemistry, US, Bristol Myers Squibb, Cancer, State university system, Mount Sinai Medical Center, NK, Albert Einstein College of Medicine, BMS, State University of New York Upstate Medical University, GC, Rituximab, University School, New York University Grossman School of Medicine, Northwest Biotherapeutics, Infection, Pharmaceutical industry, Neuroscience

Dr. Bessen brings to Artiva two decades of global pharmaceutical industry experience in medical leadership roles spanning clinical development, medical affairs, and product launches.

Key Points: 
  • Dr. Bessen brings to Artiva two decades of global pharmaceutical industry experience in medical leadership roles spanning clinical development, medical affairs, and product launches.
  • Laura has an impressive track record, with extensive experience in late-stage clinical development, product launches, and patient access, said Fred Aslan, M.D., Chief Executive Officer of Artiva.
  • Dr. Bessen retired in 2016 from Bristol Myers Squibb (BMS) after 15 years in leadership positions, most recently as Vice President, Head of US Medical.
  • She currently provides strategic and board level advice as managing partner of Maxsam Advisors LLC.

Worldwide Oral Cancer Treatment Industry to 2030 - Featuring Cipla, Sanofi and Teva Pharmaceuticals Industries Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 3, 2022
Pharmaceutical, Health, Oncology, Oral, Oral cancer, Recurrence, Death, Immunotherapy, Treatment, Woman, Prevalence, Risk, Mouth, Awareness, Human papillomavirus infection, Growth, Head, Man, Disease, Profile, Smokeless tobacco, National Cancer Institute, Exocrine gland, Squamous cell carcinoma, CAGR, Tongue, Malignancy, Oropharyngeal cancer, National, Neoplasm, Dentistry, Birth control

The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Key Points: 
  • The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.
  • Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor.
  • Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S.
  • The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region.

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 3, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Administration, Private Securities Litigation Reform Act, Public expenditure, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Bio, PAH, Patient, G&A, Â, Ulcerative colitis, Industry, Gossamer, Food, Security (finance), Entrepreneurship, U.S. Securities and Exchange Commission, FDA, SEC, Company, UC, Research and development, Disease, Inflammation, GOSS, Clinical trial, IND, Review, R, IBD, IPR, Nasdaq, Therapy, Pharmaceutical industry, Lithium, PCNSL, COVID-19

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
  • Treat through week 36 topline data from the Phase 2 SHIFT-UC study in patients with mild-to-moderate UC are expected in the fourth quarter of 2022.
  • Financial Results for Quarter and Full Year Ended December 31, 2021
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2021, were $325.2 million.
  • ET today, Thursday, March 3, to discuss its fourth quarter and full year 2021 financial results and provide a corporate update.